Tags

Type your tag names separated by a space and hit enter

Lovastatin therapy reduces low density lipoprotein apoB levels in subjects with combined hyperlipidemia by reducing the production of apoB-containing lipoproteins: implications for the pathophysiology of apoB production.
J Lipid Res. 1990 Apr; 31(4):567-82.JL

Abstract

We investigated the metabolism of very low density lipoprotein (VLDL), intermediate density lipoprotein (IDL), and low density lipoprotein (LDL) apolipoprotein B (apoB) in seven patients with combined hyperlipidemia (CHL), using 125I-labeled VLDL and 131I-labeled LDL and compartmental modeling, before and during lovastatin treatment. Lovastatin therapy significantly reduced plasma levels of LDL cholesterol (142 vs 93 mg/dl, P less than 0.0005) and apoB (1328 vs 797 micrograms/ml, P less than 0.001). Before treatment, CHL patients had high production rates (PR) of LDL apoB. Three-fourths of this LDL apoB flux was derived from sources other than circulating VLDL and was, therefore, defined as "cold" LDL apoB flux. Compared to baseline, treatment with lovastatin was associated with a significant reduction in the total rate of entry of apoB-containing lipoproteins into plasma in all seven CHL subjects (40.7 vs. 25.7 mg/kg.day, P less than 0.003). This reduction was associated with a fall in total LDL apoB PR and in "cold" LDL apoB PR in six out of seven CHL subjects. VLDL apoB PR fell in five out of seven CHL subjects. Treatment with lovastatin did not significantly alter VLDL apoB conversion to LDL apoB or LDL apoB fractional catabolic rate (FCR) in CHL patients. In three patients with familial hypercholesterolemia who were studied for comparison, lovastatin treatment increased LDL apoB FCR but did not consistently alter LDL apoB PR. We conclude that lovastatin lowers LDL cholesterol and apoB concentrations in CHL patients by reducing the rate of entry of apoB-containing lipoproteins into plasma, either as VLDL or as directly secreted LDL.

Authors+Show Affiliations

Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY 10032.No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, U.S. Gov't, P.H.S.

Language

eng

PubMed ID

2351867

Citation

Arad, Y, et al. "Lovastatin Therapy Reduces Low Density Lipoprotein apoB Levels in Subjects With Combined Hyperlipidemia By Reducing the Production of apoB-containing Lipoproteins: Implications for the Pathophysiology of apoB Production." Journal of Lipid Research, vol. 31, no. 4, 1990, pp. 567-82.
Arad Y, Ramakrishnan R, Ginsberg HN. Lovastatin therapy reduces low density lipoprotein apoB levels in subjects with combined hyperlipidemia by reducing the production of apoB-containing lipoproteins: implications for the pathophysiology of apoB production. J Lipid Res. 1990;31(4):567-82.
Arad, Y., Ramakrishnan, R., & Ginsberg, H. N. (1990). Lovastatin therapy reduces low density lipoprotein apoB levels in subjects with combined hyperlipidemia by reducing the production of apoB-containing lipoproteins: implications for the pathophysiology of apoB production. Journal of Lipid Research, 31(4), 567-82.
Arad Y, Ramakrishnan R, Ginsberg HN. Lovastatin Therapy Reduces Low Density Lipoprotein apoB Levels in Subjects With Combined Hyperlipidemia By Reducing the Production of apoB-containing Lipoproteins: Implications for the Pathophysiology of apoB Production. J Lipid Res. 1990;31(4):567-82. PubMed PMID: 2351867.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Lovastatin therapy reduces low density lipoprotein apoB levels in subjects with combined hyperlipidemia by reducing the production of apoB-containing lipoproteins: implications for the pathophysiology of apoB production. AU - Arad,Y, AU - Ramakrishnan,R, AU - Ginsberg,H N, PY - 1990/4/1/pubmed PY - 1990/4/1/medline PY - 1990/4/1/entrez SP - 567 EP - 82 JF - Journal of lipid research JO - J. Lipid Res. VL - 31 IS - 4 N2 - We investigated the metabolism of very low density lipoprotein (VLDL), intermediate density lipoprotein (IDL), and low density lipoprotein (LDL) apolipoprotein B (apoB) in seven patients with combined hyperlipidemia (CHL), using 125I-labeled VLDL and 131I-labeled LDL and compartmental modeling, before and during lovastatin treatment. Lovastatin therapy significantly reduced plasma levels of LDL cholesterol (142 vs 93 mg/dl, P less than 0.0005) and apoB (1328 vs 797 micrograms/ml, P less than 0.001). Before treatment, CHL patients had high production rates (PR) of LDL apoB. Three-fourths of this LDL apoB flux was derived from sources other than circulating VLDL and was, therefore, defined as "cold" LDL apoB flux. Compared to baseline, treatment with lovastatin was associated with a significant reduction in the total rate of entry of apoB-containing lipoproteins into plasma in all seven CHL subjects (40.7 vs. 25.7 mg/kg.day, P less than 0.003). This reduction was associated with a fall in total LDL apoB PR and in "cold" LDL apoB PR in six out of seven CHL subjects. VLDL apoB PR fell in five out of seven CHL subjects. Treatment with lovastatin did not significantly alter VLDL apoB conversion to LDL apoB or LDL apoB fractional catabolic rate (FCR) in CHL patients. In three patients with familial hypercholesterolemia who were studied for comparison, lovastatin treatment increased LDL apoB FCR but did not consistently alter LDL apoB PR. We conclude that lovastatin lowers LDL cholesterol and apoB concentrations in CHL patients by reducing the rate of entry of apoB-containing lipoproteins into plasma, either as VLDL or as directly secreted LDL. SN - 0022-2275 UR - https://www.unboundmedicine.com/medline/citation/2351867/Lovastatin_therapy_reduces_low_density_lipoprotein_apoB_levels_in_subjects_with_combined_hyperlipidemia_by_reducing_the_production_of_apoB_containing_lipoproteins:_implications_for_the_pathophysiology_of_apoB_production_ L2 - http://www.jlr.org/cgi/pmidlookup?view=long&pmid=2351867 DB - PRIME DP - Unbound Medicine ER -